nodes	percent_of_prediction	percent_of_DWPC	metapath
Bisoprolol—ADRB2—prostate cancer	0.254	0.646	CbGaD
Bisoprolol—CYP3A4—prostate cancer	0.139	0.354	CbGaD
Bisoprolol—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0532	0.154	CbGbCtD
Bisoprolol—CYP2D6—Bicalutamide—prostate cancer	0.044	0.128	CbGbCtD
Bisoprolol—CYP2D6—Abiraterone—prostate cancer	0.0364	0.106	CbGbCtD
Bisoprolol—CYP3A4—Bicalutamide—prostate cancer	0.028	0.0811	CbGbCtD
Bisoprolol—CYP3A4—Estramustine—prostate cancer	0.026	0.0754	CbGbCtD
Bisoprolol—CYP3A4—Flutamide—prostate cancer	0.0232	0.0672	CbGbCtD
Bisoprolol—CYP3A4—Abiraterone—prostate cancer	0.0232	0.0672	CbGbCtD
Bisoprolol—CYP3A4—Cabazitaxel—prostate cancer	0.0171	0.0497	CbGbCtD
Bisoprolol—CYP3A4—Estrone—prostate cancer	0.0168	0.0486	CbGbCtD
Bisoprolol—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0149	0.0433	CbGbCtD
Bisoprolol—CYP3A4—Conjugated Estrogens—prostate cancer	0.011	0.0318	CbGbCtD
Bisoprolol—CYP3A4—Mitoxantrone—prostate cancer	0.00996	0.0289	CbGbCtD
Bisoprolol—CYP3A4—Estradiol—prostate cancer	0.00962	0.0279	CbGbCtD
Bisoprolol—CYP3A4—Prednisone—prostate cancer	0.00827	0.024	CbGbCtD
Bisoprolol—CYP2D6—Doxorubicin—prostate cancer	0.00674	0.0196	CbGbCtD
Bisoprolol—CYP3A4—Etoposide—prostate cancer	0.00628	0.0182	CbGbCtD
Bisoprolol—CYP3A4—Docetaxel—prostate cancer	0.00575	0.0167	CbGbCtD
Bisoprolol—CYP3A4—Doxorubicin—prostate cancer	0.00429	0.0124	CbGbCtD
Bisoprolol—Acebutolol—SLC22A1—prostate cancer	0.000394	0.099	CrCbGaD
Bisoprolol—Chlorphenesin—CYP19A1—prostate cancer	0.000318	0.0798	CrCbGaD
Bisoprolol—Esmolol—ADRB2—prostate cancer	0.000313	0.0784	CrCbGaD
Bisoprolol—Bevantolol—ADRB2—prostate cancer	0.000309	0.0775	CrCbGaD
Bisoprolol—Betaxolol—ADRB2—prostate cancer	0.000275	0.0691	CrCbGaD
Bisoprolol—Atenolol—ADRB2—prostate cancer	0.000273	0.0684	CrCbGaD
Bisoprolol—Acebutolol—ADRB2—prostate cancer	0.000252	0.0632	CrCbGaD
Bisoprolol—Oxprenolol—ADRB2—prostate cancer	0.00025	0.0627	CrCbGaD
Bisoprolol—Alprenolol—ADRB2—prostate cancer	0.000229	0.0574	CrCbGaD
Bisoprolol—Metoprolol—ADRB2—prostate cancer	0.000212	0.0533	CrCbGaD
Bisoprolol—Pindolol—ADRB2—prostate cancer	0.000197	0.0493	CrCbGaD
Bisoprolol—Metoprolol—CYP2C19—prostate cancer	0.000183	0.0459	CrCbGaD
Bisoprolol—Chlorphenesin—CYP3A4—prostate cancer	0.000149	0.0375	CrCbGaD
Bisoprolol—Chlorphenesin—PTGS2—prostate cancer	0.000146	0.0367	CrCbGaD
Bisoprolol—Propranolol—CYP3A5—prostate cancer	0.000136	0.034	CrCbGaD
Bisoprolol—Propranolol—ADRB2—prostate cancer	0.000107	0.0269	CrCbGaD
Bisoprolol—Propranolol—CYP2C19—prostate cancer	9.23e-05	0.0232	CrCbGaD
Bisoprolol—Propranolol—CYP1A1—prostate cancer	9.2e-05	0.0231	CrCbGaD
Bisoprolol—Propranolol—CYP3A4—prostate cancer	5.87e-05	0.0147	CrCbGaD
Bisoprolol—Vertigo—Prednisone—prostate cancer	4.37e-05	0.000214	CcSEcCtD
Bisoprolol—Hepatitis—Epirubicin—prostate cancer	4.37e-05	0.000214	CcSEcCtD
Bisoprolol—Thrombocytopenia—Capecitabine—prostate cancer	4.36e-05	0.000214	CcSEcCtD
Bisoprolol—Syncope—Prednisone—prostate cancer	4.36e-05	0.000214	CcSEcCtD
Bisoprolol—Tachycardia—Capecitabine—prostate cancer	4.35e-05	0.000213	CcSEcCtD
Bisoprolol—Hypoaesthesia—Epirubicin—prostate cancer	4.35e-05	0.000213	CcSEcCtD
Bisoprolol—Pharyngitis—Epirubicin—prostate cancer	4.34e-05	0.000213	CcSEcCtD
Bisoprolol—Skin disorder—Capecitabine—prostate cancer	4.33e-05	0.000212	CcSEcCtD
Bisoprolol—Sweating—Doxorubicin—prostate cancer	4.32e-05	0.000212	CcSEcCtD
Bisoprolol—Hyperhidrosis—Capecitabine—prostate cancer	4.31e-05	0.000211	CcSEcCtD
Bisoprolol—Oedema peripheral—Epirubicin—prostate cancer	4.31e-05	0.000211	CcSEcCtD
Bisoprolol—Hypotension—Docetaxel—prostate cancer	4.3e-05	0.000211	CcSEcCtD
Bisoprolol—Connective tissue disorder—Epirubicin—prostate cancer	4.3e-05	0.000211	CcSEcCtD
Bisoprolol—Loss of consciousness—Prednisone—prostate cancer	4.28e-05	0.00021	CcSEcCtD
Bisoprolol—Hepatobiliary disease—Doxorubicin—prostate cancer	4.26e-05	0.000209	CcSEcCtD
Bisoprolol—Nausea—Estradiol—prostate cancer	4.25e-05	0.000208	CcSEcCtD
Bisoprolol—Vomiting—Mitoxantrone—prostate cancer	4.24e-05	0.000208	CcSEcCtD
Bisoprolol—Sinusitis—Doxorubicin—prostate cancer	4.23e-05	0.000207	CcSEcCtD
Bisoprolol—Visual impairment—Epirubicin—prostate cancer	4.21e-05	0.000207	CcSEcCtD
Bisoprolol—Agranulocytosis—Doxorubicin—prostate cancer	4.2e-05	0.000206	CcSEcCtD
Bisoprolol—Rash—Mitoxantrone—prostate cancer	4.2e-05	0.000206	CcSEcCtD
Bisoprolol—Dermatitis—Mitoxantrone—prostate cancer	4.2e-05	0.000206	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.2e-05	0.000206	CcSEcCtD
Bisoprolol—Headache—Mitoxantrone—prostate cancer	4.17e-05	0.000205	CcSEcCtD
Bisoprolol—Hypotension—Capecitabine—prostate cancer	4.17e-05	0.000204	CcSEcCtD
Bisoprolol—Insomnia—Docetaxel—prostate cancer	4.16e-05	0.000204	CcSEcCtD
Bisoprolol—Arthralgia—Prednisone—prostate cancer	4.14e-05	0.000203	CcSEcCtD
Bisoprolol—Myalgia—Prednisone—prostate cancer	4.14e-05	0.000203	CcSEcCtD
Bisoprolol—Paraesthesia—Docetaxel—prostate cancer	4.13e-05	0.000203	CcSEcCtD
Bisoprolol—Anxiety—Prednisone—prostate cancer	4.13e-05	0.000202	CcSEcCtD
Bisoprolol—Bradycardia—Doxorubicin—prostate cancer	4.12e-05	0.000202	CcSEcCtD
Bisoprolol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	4.11e-05	0.000202	CcSEcCtD
Bisoprolol—Dyspnoea—Docetaxel—prostate cancer	4.11e-05	0.000201	CcSEcCtD
Bisoprolol—Somnolence—Docetaxel—prostate cancer	4.09e-05	0.000201	CcSEcCtD
Bisoprolol—Discomfort—Prednisone—prostate cancer	4.09e-05	0.000201	CcSEcCtD
Bisoprolol—Eye disorder—Epirubicin—prostate cancer	4.09e-05	0.0002	CcSEcCtD
Bisoprolol—Hypersensitivity—Etoposide—prostate cancer	4.08e-05	0.0002	CcSEcCtD
Bisoprolol—Tinnitus—Epirubicin—prostate cancer	4.08e-05	0.0002	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Capecitabine—prostate cancer	4.06e-05	0.000199	CcSEcCtD
Bisoprolol—Cardiac disorder—Epirubicin—prostate cancer	4.06e-05	0.000199	CcSEcCtD
Bisoprolol—Flushing—Epirubicin—prostate cancer	4.06e-05	0.000199	CcSEcCtD
Bisoprolol—Rhinitis—Doxorubicin—prostate cancer	4.06e-05	0.000199	CcSEcCtD
Bisoprolol—Dyspepsia—Docetaxel—prostate cancer	4.05e-05	0.000199	CcSEcCtD
Bisoprolol—Hepatitis—Doxorubicin—prostate cancer	4.04e-05	0.000198	CcSEcCtD
Bisoprolol—Insomnia—Capecitabine—prostate cancer	4.03e-05	0.000198	CcSEcCtD
Bisoprolol—Hypoaesthesia—Doxorubicin—prostate cancer	4.02e-05	0.000197	CcSEcCtD
Bisoprolol—Pharyngitis—Doxorubicin—prostate cancer	4.01e-05	0.000197	CcSEcCtD
Bisoprolol—Paraesthesia—Capecitabine—prostate cancer	4e-05	0.000196	CcSEcCtD
Bisoprolol—Oedema peripheral—Doxorubicin—prostate cancer	3.98e-05	0.000195	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Docetaxel—prostate cancer	3.98e-05	0.000195	CcSEcCtD
Bisoprolol—Asthenia—Etoposide—prostate cancer	3.98e-05	0.000195	CcSEcCtD
Bisoprolol—Connective tissue disorder—Doxorubicin—prostate cancer	3.97e-05	0.000195	CcSEcCtD
Bisoprolol—Dyspnoea—Capecitabine—prostate cancer	3.97e-05	0.000195	CcSEcCtD
Bisoprolol—Oedema—Prednisone—prostate cancer	3.97e-05	0.000195	CcSEcCtD
Bisoprolol—Fatigue—Docetaxel—prostate cancer	3.97e-05	0.000195	CcSEcCtD
Bisoprolol—Angiopathy—Epirubicin—prostate cancer	3.97e-05	0.000195	CcSEcCtD
Bisoprolol—Nausea—Mitoxantrone—prostate cancer	3.96e-05	0.000194	CcSEcCtD
Bisoprolol—Infection—Prednisone—prostate cancer	3.95e-05	0.000193	CcSEcCtD
Bisoprolol—Mediastinal disorder—Epirubicin—prostate cancer	3.94e-05	0.000193	CcSEcCtD
Bisoprolol—Constipation—Docetaxel—prostate cancer	3.94e-05	0.000193	CcSEcCtD
Bisoprolol—Pain—Docetaxel—prostate cancer	3.94e-05	0.000193	CcSEcCtD
Bisoprolol—Dyspepsia—Capecitabine—prostate cancer	3.92e-05	0.000192	CcSEcCtD
Bisoprolol—Pruritus—Etoposide—prostate cancer	3.92e-05	0.000192	CcSEcCtD
Bisoprolol—Shock—Prednisone—prostate cancer	3.91e-05	0.000192	CcSEcCtD
Bisoprolol—Arrhythmia—Epirubicin—prostate cancer	3.91e-05	0.000192	CcSEcCtD
Bisoprolol—Visual impairment—Doxorubicin—prostate cancer	3.9e-05	0.000191	CcSEcCtD
Bisoprolol—Nervous system disorder—Prednisone—prostate cancer	3.89e-05	0.000191	CcSEcCtD
Bisoprolol—Tachycardia—Prednisone—prostate cancer	3.88e-05	0.00019	CcSEcCtD
Bisoprolol—Alopecia—Epirubicin—prostate cancer	3.86e-05	0.000189	CcSEcCtD
Bisoprolol—Skin disorder—Prednisone—prostate cancer	3.86e-05	0.000189	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Capecitabine—prostate cancer	3.85e-05	0.000189	CcSEcCtD
Bisoprolol—Fatigue—Capecitabine—prostate cancer	3.84e-05	0.000188	CcSEcCtD
Bisoprolol—Hyperhidrosis—Prednisone—prostate cancer	3.84e-05	0.000188	CcSEcCtD
Bisoprolol—Mental disorder—Epirubicin—prostate cancer	3.83e-05	0.000188	CcSEcCtD
Bisoprolol—Pain—Capecitabine—prostate cancer	3.81e-05	0.000187	CcSEcCtD
Bisoprolol—Constipation—Capecitabine—prostate cancer	3.81e-05	0.000187	CcSEcCtD
Bisoprolol—Erythema—Epirubicin—prostate cancer	3.81e-05	0.000187	CcSEcCtD
Bisoprolol—Feeling abnormal—Docetaxel—prostate cancer	3.79e-05	0.000186	CcSEcCtD
Bisoprolol—Diarrhoea—Etoposide—prostate cancer	3.79e-05	0.000186	CcSEcCtD
Bisoprolol—Eye disorder—Doxorubicin—prostate cancer	3.78e-05	0.000185	CcSEcCtD
Bisoprolol—Tinnitus—Doxorubicin—prostate cancer	3.77e-05	0.000185	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Docetaxel—prostate cancer	3.77e-05	0.000185	CcSEcCtD
Bisoprolol—Flushing—Doxorubicin—prostate cancer	3.75e-05	0.000184	CcSEcCtD
Bisoprolol—Cardiac disorder—Doxorubicin—prostate cancer	3.75e-05	0.000184	CcSEcCtD
Bisoprolol—Dysgeusia—Epirubicin—prostate cancer	3.73e-05	0.000183	CcSEcCtD
Bisoprolol—Back pain—Epirubicin—prostate cancer	3.68e-05	0.000181	CcSEcCtD
Bisoprolol—Feeling abnormal—Capecitabine—prostate cancer	3.67e-05	0.00018	CcSEcCtD
Bisoprolol—Angiopathy—Doxorubicin—prostate cancer	3.67e-05	0.00018	CcSEcCtD
Bisoprolol—Dizziness—Etoposide—prostate cancer	3.66e-05	0.00018	CcSEcCtD
Bisoprolol—Muscle spasms—Epirubicin—prostate cancer	3.66e-05	0.000179	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Capecitabine—prostate cancer	3.65e-05	0.000179	CcSEcCtD
Bisoprolol—Mediastinal disorder—Doxorubicin—prostate cancer	3.65e-05	0.000179	CcSEcCtD
Bisoprolol—Abdominal pain—Docetaxel—prostate cancer	3.64e-05	0.000179	CcSEcCtD
Bisoprolol—Body temperature increased—Docetaxel—prostate cancer	3.64e-05	0.000179	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Prednisone—prostate cancer	3.62e-05	0.000177	CcSEcCtD
Bisoprolol—Arrhythmia—Doxorubicin—prostate cancer	3.61e-05	0.000177	CcSEcCtD
Bisoprolol—Insomnia—Prednisone—prostate cancer	3.59e-05	0.000176	CcSEcCtD
Bisoprolol—Alopecia—Doxorubicin—prostate cancer	3.57e-05	0.000175	CcSEcCtD
Bisoprolol—Paraesthesia—Prednisone—prostate cancer	3.57e-05	0.000175	CcSEcCtD
Bisoprolol—Mental disorder—Doxorubicin—prostate cancer	3.54e-05	0.000174	CcSEcCtD
Bisoprolol—Urticaria—Capecitabine—prostate cancer	3.54e-05	0.000174	CcSEcCtD
Bisoprolol—Ill-defined disorder—Epirubicin—prostate cancer	3.53e-05	0.000173	CcSEcCtD
Bisoprolol—Abdominal pain—Capecitabine—prostate cancer	3.52e-05	0.000173	CcSEcCtD
Bisoprolol—Body temperature increased—Capecitabine—prostate cancer	3.52e-05	0.000173	CcSEcCtD
Bisoprolol—Vomiting—Etoposide—prostate cancer	3.52e-05	0.000173	CcSEcCtD
Bisoprolol—Erythema—Doxorubicin—prostate cancer	3.52e-05	0.000173	CcSEcCtD
Bisoprolol—Agitation—Epirubicin—prostate cancer	3.5e-05	0.000171	CcSEcCtD
Bisoprolol—Dyspepsia—Prednisone—prostate cancer	3.5e-05	0.000171	CcSEcCtD
Bisoprolol—Rash—Etoposide—prostate cancer	3.49e-05	0.000171	CcSEcCtD
Bisoprolol—Dermatitis—Etoposide—prostate cancer	3.49e-05	0.000171	CcSEcCtD
Bisoprolol—Headache—Etoposide—prostate cancer	3.47e-05	0.00017	CcSEcCtD
Bisoprolol—Dysgeusia—Doxorubicin—prostate cancer	3.45e-05	0.000169	CcSEcCtD
Bisoprolol—Malaise—Epirubicin—prostate cancer	3.43e-05	0.000168	CcSEcCtD
Bisoprolol—Fatigue—Prednisone—prostate cancer	3.42e-05	0.000168	CcSEcCtD
Bisoprolol—Vertigo—Epirubicin—prostate cancer	3.42e-05	0.000168	CcSEcCtD
Bisoprolol—Syncope—Epirubicin—prostate cancer	3.41e-05	0.000167	CcSEcCtD
Bisoprolol—Back pain—Doxorubicin—prostate cancer	3.41e-05	0.000167	CcSEcCtD
Bisoprolol—Constipation—Prednisone—prostate cancer	3.4e-05	0.000167	CcSEcCtD
Bisoprolol—Hypersensitivity—Docetaxel—prostate cancer	3.39e-05	0.000166	CcSEcCtD
Bisoprolol—Muscle spasms—Doxorubicin—prostate cancer	3.39e-05	0.000166	CcSEcCtD
Bisoprolol—Palpitations—Epirubicin—prostate cancer	3.36e-05	0.000165	CcSEcCtD
Bisoprolol—Loss of consciousness—Epirubicin—prostate cancer	3.34e-05	0.000164	CcSEcCtD
Bisoprolol—Cough—Epirubicin—prostate cancer	3.32e-05	0.000163	CcSEcCtD
Bisoprolol—Asthenia—Docetaxel—prostate cancer	3.3e-05	0.000162	CcSEcCtD
Bisoprolol—Nausea—Etoposide—prostate cancer	3.29e-05	0.000161	CcSEcCtD
Bisoprolol—Hypersensitivity—Capecitabine—prostate cancer	3.28e-05	0.000161	CcSEcCtD
Bisoprolol—Feeling abnormal—Prednisone—prostate cancer	3.27e-05	0.00016	CcSEcCtD
Bisoprolol—Ill-defined disorder—Doxorubicin—prostate cancer	3.27e-05	0.00016	CcSEcCtD
Bisoprolol—Pruritus—Docetaxel—prostate cancer	3.26e-05	0.00016	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Prednisone—prostate cancer	3.25e-05	0.000159	CcSEcCtD
Bisoprolol—Myalgia—Epirubicin—prostate cancer	3.24e-05	0.000159	CcSEcCtD
Bisoprolol—Chest pain—Epirubicin—prostate cancer	3.24e-05	0.000159	CcSEcCtD
Bisoprolol—Arthralgia—Epirubicin—prostate cancer	3.24e-05	0.000159	CcSEcCtD
Bisoprolol—Agitation—Doxorubicin—prostate cancer	3.24e-05	0.000159	CcSEcCtD
Bisoprolol—Anxiety—Epirubicin—prostate cancer	3.23e-05	0.000158	CcSEcCtD
Bisoprolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.22e-05	0.000158	CcSEcCtD
Bisoprolol—Discomfort—Epirubicin—prostate cancer	3.2e-05	0.000157	CcSEcCtD
Bisoprolol—Asthenia—Capecitabine—prostate cancer	3.2e-05	0.000157	CcSEcCtD
Bisoprolol—Malaise—Doxorubicin—prostate cancer	3.18e-05	0.000156	CcSEcCtD
Bisoprolol—Dry mouth—Epirubicin—prostate cancer	3.17e-05	0.000155	CcSEcCtD
Bisoprolol—Vertigo—Doxorubicin—prostate cancer	3.16e-05	0.000155	CcSEcCtD
Bisoprolol—Syncope—Doxorubicin—prostate cancer	3.16e-05	0.000155	CcSEcCtD
Bisoprolol—Urticaria—Prednisone—prostate cancer	3.15e-05	0.000155	CcSEcCtD
Bisoprolol—Pruritus—Capecitabine—prostate cancer	3.15e-05	0.000155	CcSEcCtD
Bisoprolol—Diarrhoea—Docetaxel—prostate cancer	3.15e-05	0.000154	CcSEcCtD
Bisoprolol—Body temperature increased—Prednisone—prostate cancer	3.14e-05	0.000154	CcSEcCtD
Bisoprolol—Abdominal pain—Prednisone—prostate cancer	3.14e-05	0.000154	CcSEcCtD
Bisoprolol—Confusional state—Epirubicin—prostate cancer	3.13e-05	0.000154	CcSEcCtD
Bisoprolol—Palpitations—Doxorubicin—prostate cancer	3.11e-05	0.000153	CcSEcCtD
Bisoprolol—Oedema—Epirubicin—prostate cancer	3.11e-05	0.000152	CcSEcCtD
Bisoprolol—Loss of consciousness—Doxorubicin—prostate cancer	3.09e-05	0.000152	CcSEcCtD
Bisoprolol—Infection—Epirubicin—prostate cancer	3.09e-05	0.000151	CcSEcCtD
Bisoprolol—Cough—Doxorubicin—prostate cancer	3.07e-05	0.000151	CcSEcCtD
Bisoprolol—Shock—Epirubicin—prostate cancer	3.06e-05	0.00015	CcSEcCtD
Bisoprolol—Diarrhoea—Capecitabine—prostate cancer	3.05e-05	0.00015	CcSEcCtD
Bisoprolol—Nervous system disorder—Epirubicin—prostate cancer	3.05e-05	0.000149	CcSEcCtD
Bisoprolol—Dizziness—Docetaxel—prostate cancer	3.04e-05	0.000149	CcSEcCtD
Bisoprolol—Thrombocytopenia—Epirubicin—prostate cancer	3.04e-05	0.000149	CcSEcCtD
Bisoprolol—Tachycardia—Epirubicin—prostate cancer	3.03e-05	0.000149	CcSEcCtD
Bisoprolol—Skin disorder—Epirubicin—prostate cancer	3.02e-05	0.000148	CcSEcCtD
Bisoprolol—Hyperhidrosis—Epirubicin—prostate cancer	3e-05	0.000147	CcSEcCtD
Bisoprolol—Arthralgia—Doxorubicin—prostate cancer	3e-05	0.000147	CcSEcCtD
Bisoprolol—Chest pain—Doxorubicin—prostate cancer	3e-05	0.000147	CcSEcCtD
Bisoprolol—Myalgia—Doxorubicin—prostate cancer	3e-05	0.000147	CcSEcCtD
Bisoprolol—Anxiety—Doxorubicin—prostate cancer	2.99e-05	0.000146	CcSEcCtD
Bisoprolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.98e-05	0.000146	CcSEcCtD
Bisoprolol—Discomfort—Doxorubicin—prostate cancer	2.96e-05	0.000145	CcSEcCtD
Bisoprolol—Dizziness—Capecitabine—prostate cancer	2.95e-05	0.000145	CcSEcCtD
Bisoprolol—Dry mouth—Doxorubicin—prostate cancer	2.93e-05	0.000144	CcSEcCtD
Bisoprolol—Vomiting—Docetaxel—prostate cancer	2.93e-05	0.000144	CcSEcCtD
Bisoprolol—Hypersensitivity—Prednisone—prostate cancer	2.93e-05	0.000143	CcSEcCtD
Bisoprolol—Rash—Docetaxel—prostate cancer	2.9e-05	0.000142	CcSEcCtD
Bisoprolol—Hypotension—Epirubicin—prostate cancer	2.9e-05	0.000142	CcSEcCtD
Bisoprolol—Dermatitis—Docetaxel—prostate cancer	2.9e-05	0.000142	CcSEcCtD
Bisoprolol—Confusional state—Doxorubicin—prostate cancer	2.9e-05	0.000142	CcSEcCtD
Bisoprolol—Headache—Docetaxel—prostate cancer	2.88e-05	0.000141	CcSEcCtD
Bisoprolol—Oedema—Doxorubicin—prostate cancer	2.87e-05	0.000141	CcSEcCtD
Bisoprolol—Infection—Doxorubicin—prostate cancer	2.85e-05	0.00014	CcSEcCtD
Bisoprolol—Asthenia—Prednisone—prostate cancer	2.85e-05	0.00014	CcSEcCtD
Bisoprolol—Vomiting—Capecitabine—prostate cancer	2.83e-05	0.000139	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.83e-05	0.000139	CcSEcCtD
Bisoprolol—Shock—Doxorubicin—prostate cancer	2.83e-05	0.000139	CcSEcCtD
Bisoprolol—Nervous system disorder—Doxorubicin—prostate cancer	2.82e-05	0.000138	CcSEcCtD
Bisoprolol—Thrombocytopenia—Doxorubicin—prostate cancer	2.81e-05	0.000138	CcSEcCtD
Bisoprolol—Rash—Capecitabine—prostate cancer	2.81e-05	0.000138	CcSEcCtD
Bisoprolol—Pruritus—Prednisone—prostate cancer	2.81e-05	0.000138	CcSEcCtD
Bisoprolol—Insomnia—Epirubicin—prostate cancer	2.81e-05	0.000138	CcSEcCtD
Bisoprolol—Dermatitis—Capecitabine—prostate cancer	2.81e-05	0.000138	CcSEcCtD
Bisoprolol—Tachycardia—Doxorubicin—prostate cancer	2.8e-05	0.000138	CcSEcCtD
Bisoprolol—Headache—Capecitabine—prostate cancer	2.79e-05	0.000137	CcSEcCtD
Bisoprolol—Skin disorder—Doxorubicin—prostate cancer	2.79e-05	0.000137	CcSEcCtD
Bisoprolol—Paraesthesia—Epirubicin—prostate cancer	2.79e-05	0.000137	CcSEcCtD
Bisoprolol—Hyperhidrosis—Doxorubicin—prostate cancer	2.78e-05	0.000136	CcSEcCtD
Bisoprolol—Dyspnoea—Epirubicin—prostate cancer	2.77e-05	0.000136	CcSEcCtD
Bisoprolol—Somnolence—Epirubicin—prostate cancer	2.76e-05	0.000135	CcSEcCtD
Bisoprolol—Nausea—Docetaxel—prostate cancer	2.73e-05	0.000134	CcSEcCtD
Bisoprolol—Dyspepsia—Epirubicin—prostate cancer	2.73e-05	0.000134	CcSEcCtD
Bisoprolol—Diarrhoea—Prednisone—prostate cancer	2.72e-05	0.000133	CcSEcCtD
Bisoprolol—Hypotension—Doxorubicin—prostate cancer	2.69e-05	0.000132	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Epirubicin—prostate cancer	2.68e-05	0.000131	CcSEcCtD
Bisoprolol—Fatigue—Epirubicin—prostate cancer	2.68e-05	0.000131	CcSEcCtD
Bisoprolol—Pain—Epirubicin—prostate cancer	2.66e-05	0.00013	CcSEcCtD
Bisoprolol—Constipation—Epirubicin—prostate cancer	2.66e-05	0.00013	CcSEcCtD
Bisoprolol—Nausea—Capecitabine—prostate cancer	2.65e-05	0.00013	CcSEcCtD
Bisoprolol—Dizziness—Prednisone—prostate cancer	2.63e-05	0.000129	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.62e-05	0.000128	CcSEcCtD
Bisoprolol—Insomnia—Doxorubicin—prostate cancer	2.6e-05	0.000127	CcSEcCtD
Bisoprolol—Paraesthesia—Doxorubicin—prostate cancer	2.58e-05	0.000127	CcSEcCtD
Bisoprolol—Dyspnoea—Doxorubicin—prostate cancer	2.56e-05	0.000126	CcSEcCtD
Bisoprolol—Feeling abnormal—Epirubicin—prostate cancer	2.56e-05	0.000126	CcSEcCtD
Bisoprolol—Somnolence—Doxorubicin—prostate cancer	2.55e-05	0.000125	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Epirubicin—prostate cancer	2.54e-05	0.000125	CcSEcCtD
Bisoprolol—Dyspepsia—Doxorubicin—prostate cancer	2.53e-05	0.000124	CcSEcCtD
Bisoprolol—Vomiting—Prednisone—prostate cancer	2.52e-05	0.000124	CcSEcCtD
Bisoprolol—Rash—Prednisone—prostate cancer	2.5e-05	0.000123	CcSEcCtD
Bisoprolol—Dermatitis—Prednisone—prostate cancer	2.5e-05	0.000123	CcSEcCtD
Bisoprolol—Headache—Prednisone—prostate cancer	2.49e-05	0.000122	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.48e-05	0.000122	CcSEcCtD
Bisoprolol—Fatigue—Doxorubicin—prostate cancer	2.48e-05	0.000121	CcSEcCtD
Bisoprolol—Urticaria—Epirubicin—prostate cancer	2.47e-05	0.000121	CcSEcCtD
Bisoprolol—Constipation—Doxorubicin—prostate cancer	2.46e-05	0.000121	CcSEcCtD
Bisoprolol—Pain—Doxorubicin—prostate cancer	2.46e-05	0.000121	CcSEcCtD
Bisoprolol—Body temperature increased—Epirubicin—prostate cancer	2.46e-05	0.00012	CcSEcCtD
Bisoprolol—Abdominal pain—Epirubicin—prostate cancer	2.46e-05	0.00012	CcSEcCtD
Bisoprolol—Feeling abnormal—Doxorubicin—prostate cancer	2.37e-05	0.000116	CcSEcCtD
Bisoprolol—Nausea—Prednisone—prostate cancer	2.36e-05	0.000116	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Doxorubicin—prostate cancer	2.35e-05	0.000115	CcSEcCtD
Bisoprolol—Hypersensitivity—Epirubicin—prostate cancer	2.29e-05	0.000112	CcSEcCtD
Bisoprolol—Urticaria—Doxorubicin—prostate cancer	2.28e-05	0.000112	CcSEcCtD
Bisoprolol—Abdominal pain—Doxorubicin—prostate cancer	2.27e-05	0.000111	CcSEcCtD
Bisoprolol—Body temperature increased—Doxorubicin—prostate cancer	2.27e-05	0.000111	CcSEcCtD
Bisoprolol—Asthenia—Epirubicin—prostate cancer	2.23e-05	0.000109	CcSEcCtD
Bisoprolol—Pruritus—Epirubicin—prostate cancer	2.2e-05	0.000108	CcSEcCtD
Bisoprolol—Diarrhoea—Epirubicin—prostate cancer	2.12e-05	0.000104	CcSEcCtD
Bisoprolol—Hypersensitivity—Doxorubicin—prostate cancer	2.12e-05	0.000104	CcSEcCtD
Bisoprolol—Asthenia—Doxorubicin—prostate cancer	2.06e-05	0.000101	CcSEcCtD
Bisoprolol—Dizziness—Epirubicin—prostate cancer	2.05e-05	0.000101	CcSEcCtD
Bisoprolol—Pruritus—Doxorubicin—prostate cancer	2.03e-05	9.97e-05	CcSEcCtD
Bisoprolol—Vomiting—Epirubicin—prostate cancer	1.97e-05	9.68e-05	CcSEcCtD
Bisoprolol—Diarrhoea—Doxorubicin—prostate cancer	1.97e-05	9.64e-05	CcSEcCtD
Bisoprolol—Rash—Epirubicin—prostate cancer	1.96e-05	9.6e-05	CcSEcCtD
Bisoprolol—Dermatitis—Epirubicin—prostate cancer	1.96e-05	9.59e-05	CcSEcCtD
Bisoprolol—Headache—Epirubicin—prostate cancer	1.95e-05	9.54e-05	CcSEcCtD
Bisoprolol—Dizziness—Doxorubicin—prostate cancer	1.9e-05	9.32e-05	CcSEcCtD
Bisoprolol—Nausea—Epirubicin—prostate cancer	1.84e-05	9.05e-05	CcSEcCtD
Bisoprolol—Vomiting—Doxorubicin—prostate cancer	1.83e-05	8.96e-05	CcSEcCtD
Bisoprolol—Rash—Doxorubicin—prostate cancer	1.81e-05	8.89e-05	CcSEcCtD
Bisoprolol—Dermatitis—Doxorubicin—prostate cancer	1.81e-05	8.88e-05	CcSEcCtD
Bisoprolol—Headache—Doxorubicin—prostate cancer	1.8e-05	8.83e-05	CcSEcCtD
Bisoprolol—Nausea—Doxorubicin—prostate cancer	1.71e-05	8.37e-05	CcSEcCtD
Bisoprolol—CYP3A4—Metabolism—SRD5A1—prostate cancer	8.48e-06	0.000155	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—ITPR1—prostate cancer	8.47e-06	0.000155	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TGFBR2—prostate cancer	8.42e-06	0.000154	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—PIK3CB—prostate cancer	8.39e-06	0.000153	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—SULT2A1—prostate cancer	8.36e-06	0.000153	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—ITPR1—prostate cancer	8.28e-06	0.000151	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—MED12—prostate cancer	8.22e-06	0.00015	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—PIK3CB—prostate cancer	8.2e-06	0.00015	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GNG5—prostate cancer	8.16e-06	0.000149	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—IGF1R—prostate cancer	8.09e-06	0.000148	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—HSD17B3—prostate cancer	8.09e-06	0.000148	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ACSL4—prostate cancer	8.09e-06	0.000148	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—CXCL8—prostate cancer	8.06e-06	0.000147	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—JAK2—prostate cancer	8.02e-06	0.000147	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—IGF1R—prostate cancer	7.92e-06	0.000145	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—CXCL8—prostate cancer	7.88e-06	0.000144	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—NCOA3—prostate cancer	7.86e-06	0.000144	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—JAK2—prostate cancer	7.84e-06	0.000143	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—LPL—prostate cancer	7.76e-06	0.000142	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PHGDH—prostate cancer	7.76e-06	0.000142	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—UMPS—prostate cancer	7.76e-06	0.000142	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ARG2—prostate cancer	7.76e-06	0.000142	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—IL2—prostate cancer	7.7e-06	0.000141	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PDGFRB—prostate cancer	7.69e-06	0.000141	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PIK3CB—prostate cancer	7.61e-06	0.000139	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—LDHB—prostate cancer	7.61e-06	0.000139	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—LPL—prostate cancer	7.59e-06	0.000139	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—IL2—prostate cancer	7.53e-06	0.000138	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PDGFRB—prostate cancer	7.52e-06	0.000138	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—HPGDS—prostate cancer	7.5e-06	0.000137	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—ITGB3—prostate cancer	7.49e-06	0.000137	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CYP3A5—prostate cancer	7.47e-06	0.000137	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CYP2C19—prostate cancer	7.45e-06	0.000136	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PIK3CB—prostate cancer	7.45e-06	0.000136	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—ITGB3—prostate cancer	7.33e-06	0.000134	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—CXCL8—prostate cancer	7.32e-06	0.000134	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ACHE—prostate cancer	7.27e-06	0.000133	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GSTT1—prostate cancer	7.27e-06	0.000133	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—ERBB3—prostate cancer	7.27e-06	0.000133	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—FGFR2—prostate cancer	7.26e-06	0.000133	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTA3—prostate cancer	7.21e-06	0.000132	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PDHA1—prostate cancer	7.21e-06	0.000132	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—UCP3—prostate cancer	7.21e-06	0.000132	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—TCN2—prostate cancer	7.21e-06	0.000132	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CYP2A6—prostate cancer	7.19e-06	0.000131	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—CXCL8—prostate cancer	7.16e-06	0.000131	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—ERBB3—prostate cancer	7.11e-06	0.00013	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—FGFR2—prostate cancer	7.1e-06	0.00013	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—IL2—prostate cancer	6.99e-06	0.000128	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—AKR1C3—prostate cancer	6.99e-06	0.000128	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—TERT—prostate cancer	6.97e-06	0.000127	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PRKACB—prostate cancer	6.96e-06	0.000127	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CYP17A1—prostate cancer	6.88e-06	0.000126	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—HSD3B1—prostate cancer	6.88e-06	0.000126	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—SLC22A3—prostate cancer	6.88e-06	0.000126	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—IL2—prostate cancer	6.84e-06	0.000125	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TERT—prostate cancer	6.82e-06	0.000125	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—HIF1A—prostate cancer	6.66e-06	0.000122	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—TBXAS1—prostate cancer	6.6e-06	0.000121	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTA4—prostate cancer	6.6e-06	0.000121	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—NCOA2—prostate cancer	6.56e-06	0.00012	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—HIF1A—prostate cancer	6.52e-06	0.000119	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—LEP—prostate cancer	6.5e-06	0.000119	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CAV1—prostate cancer	6.44e-06	0.000118	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTA2—prostate cancer	6.43e-06	0.000118	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—KDR—prostate cancer	6.37e-06	0.000117	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—LEP—prostate cancer	6.36e-06	0.000116	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ABCG5—prostate cancer	6.35e-06	0.000116	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—SULT1A1—prostate cancer	6.35e-06	0.000116	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CAV1—prostate cancer	6.3e-06	0.000115	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—SLC5A5—prostate cancer	6.26e-06	0.000114	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—KDR—prostate cancer	6.23e-06	0.000114	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—ESR1—prostate cancer	6.21e-06	0.000114	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTA1—prostate cancer	6.2e-06	0.000113	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTO1—prostate cancer	6.13e-06	0.000112	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—HSD3B2—prostate cancer	6.13e-06	0.000112	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NAT2—prostate cancer	6.13e-06	0.000112	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CYP2E1—prostate cancer	6.11e-06	0.000112	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—ESR1—prostate cancer	6.08e-06	0.000111	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—BAD—prostate cancer	6.06e-06	0.000111	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—NQO1—prostate cancer	6.04e-06	0.000111	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—TH—prostate cancer	5.96e-06	0.000109	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—BAD—prostate cancer	5.93e-06	0.000108	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CYP3A4—prostate cancer	5.89e-06	0.000108	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PLCB2—prostate cancer	5.88e-06	0.000108	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—LRP2—prostate cancer	5.88e-06	0.000108	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CYP2C18—prostate cancer	5.88e-06	0.000108	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—APC—prostate cancer	5.87e-06	0.000107	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CG—prostate cancer	5.87e-06	0.000107	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—EGF—prostate cancer	5.8e-06	0.000106	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—IRS1—prostate cancer	5.8e-06	0.000106	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CYP1B1—prostate cancer	5.79e-06	0.000106	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—P4HB—prostate cancer	5.76e-06	0.000105	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—APC—prostate cancer	5.74e-06	0.000105	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CG—prostate cancer	5.74e-06	0.000105	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—IRS1—prostate cancer	5.68e-06	0.000104	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—EGF—prostate cancer	5.68e-06	0.000104	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—GSK3B—prostate cancer	5.63e-06	0.000103	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GGT1—prostate cancer	5.61e-06	0.000103	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—SLC22A1—prostate cancer	5.61e-06	0.000103	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—INS—prostate cancer	5.56e-06	0.000102	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—NCOA1—prostate cancer	5.53e-06	0.000101	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—GSK3B—prostate cancer	5.51e-06	0.000101	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—SULT2A1—prostate cancer	5.46e-06	0.0001	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CYP19A1—prostate cancer	5.45e-06	9.96e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CREBBP—prostate cancer	5.44e-06	9.96e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—INS—prostate cancer	5.44e-06	9.94e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—MED12—prostate cancer	5.38e-06	9.83e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—IGF1—prostate cancer	5.38e-06	9.83e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—EGFR—prostate cancer	5.35e-06	9.78e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GNG5—prostate cancer	5.33e-06	9.76e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CREBBP—prostate cancer	5.32e-06	9.74e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—IGF1—prostate cancer	5.26e-06	9.62e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—RXRA—prostate cancer	5.26e-06	9.62e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—EGFR—prostate cancer	5.23e-06	9.57e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MAP2K1—prostate cancer	5.19e-06	9.5e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CD—prostate cancer	5.16e-06	9.44e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NCOA3—prostate cancer	5.14e-06	9.4e-05	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—PIK3CA—prostate cancer	5.11e-06	9.35e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—SERPINE1—prostate cancer	5.1e-06	9.34e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	5.08e-06	9.3e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—COMT—prostate cancer	5.06e-06	9.26e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—KRAS—prostate cancer	5.05e-06	9.24e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	5.05e-06	9.23e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GSTP1—prostate cancer	5.04e-06	9.22e-05	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	5e-06	9.15e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	4.99e-06	9.13e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ITPR1—prostate cancer	4.96e-06	9.07e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—KRAS—prostate cancer	4.94e-06	9.04e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—FGF2—prostate cancer	4.94e-06	9.04e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—HPGDS—prostate cancer	4.9e-06	8.97e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—NOS3—prostate cancer	4.87e-06	8.91e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CYP2C19—prostate cancer	4.87e-06	8.91e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—FGF2—prostate cancer	4.83e-06	8.84e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—NOS3—prostate cancer	4.77e-06	8.72e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTT1—prostate cancer	4.75e-06	8.7e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ACHE—prostate cancer	4.75e-06	8.7e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—JAK2—prostate cancer	4.74e-06	8.66e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CYP2A6—prostate cancer	4.7e-06	8.6e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—TYMS—prostate cancer	4.69e-06	8.57e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PIK3CA—prostate cancer	4.64e-06	8.49e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—JAK2—prostate cancer	4.63e-06	8.47e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GSTM1—prostate cancer	4.63e-06	8.47e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MDM2—prostate cancer	4.62e-06	8.46e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—AKR1C3—prostate cancer	4.57e-06	8.36e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—ERBB2—prostate cancer	4.56e-06	8.34e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PRKACB—prostate cancer	4.55e-06	8.32e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—LPL—prostate cancer	4.55e-06	8.32e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	4.54e-06	8.31e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MDM2—prostate cancer	4.52e-06	8.27e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CYP17A1—prostate cancer	4.5e-06	8.23e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CB—prostate cancer	4.5e-06	8.23e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—ERBB2—prostate cancer	4.46e-06	8.16e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	4.4e-06	8.05e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CYP1A1—prostate cancer	4.39e-06	8.03e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ERCC2—prostate cancer	4.35e-06	7.97e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CXCL8—prostate cancer	4.32e-06	7.91e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NCOA2—prostate cancer	4.29e-06	7.84e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CXCL8—prostate cancer	4.23e-06	7.73e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CDKN1B—prostate cancer	4.22e-06	7.72e-05	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—AKT1—prostate cancer	4.18e-06	7.64e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CASP3—prostate cancer	4.14e-06	7.57e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—IL2—prostate cancer	4.13e-06	7.56e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	4.13e-06	7.55e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—IL6—prostate cancer	4.11e-06	7.52e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—MTHFR—prostate cancer	4.09e-06	7.49e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—SLC5A5—prostate cancer	4.09e-06	7.48e-05	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	4.08e-06	7.47e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CASP3—prostate cancer	4.05e-06	7.4e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—IL2—prostate cancer	4.04e-06	7.39e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CCND1—prostate cancer	4.03e-06	7.37e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—IL6—prostate cancer	4.02e-06	7.35e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PPARA—prostate cancer	4.02e-06	7.35e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CYP2E1—prostate cancer	4e-06	7.31e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CTNNB1—prostate cancer	3.99e-06	7.29e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NQO1—prostate cancer	3.95e-06	7.23e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CCND1—prostate cancer	3.94e-06	7.21e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MMP9—prostate cancer	3.91e-06	7.15e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	3.9e-06	7.14e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	3.9e-06	7.13e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—TH—prostate cancer	3.89e-06	7.12e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PTEN—prostate cancer	3.89e-06	7.11e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MMP9—prostate cancer	3.82e-06	7e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	3.81e-06	6.97e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PTEN—prostate cancer	3.8e-06	6.95e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—AKT1—prostate cancer	3.79e-06	6.94e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CYP1B1—prostate cancer	3.79e-06	6.93e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CAV1—prostate cancer	3.78e-06	6.91e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—AKT1—prostate cancer	3.71e-06	6.79e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—EP300—prostate cancer	3.71e-06	6.78e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GGT1—prostate cancer	3.67e-06	6.71e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—EP300—prostate cancer	3.63e-06	6.63e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NCOA1—prostate cancer	3.61e-06	6.61e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—SRC—prostate cancer	3.6e-06	6.59e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CYP19A1—prostate cancer	3.56e-06	6.51e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—SRC—prostate cancer	3.53e-06	6.45e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—VEGFA—prostate cancer	3.51e-06	6.42e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—STAT3—prostate cancer	3.48e-06	6.36e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CG—prostate cancer	3.44e-06	6.29e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—RXRA—prostate cancer	3.44e-06	6.29e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—VEGFA—prostate cancer	3.43e-06	6.28e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—STAT3—prostate cancer	3.4e-06	6.22e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—COMT—prostate cancer	3.31e-06	6.06e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTP1—prostate cancer	3.3e-06	6.03e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—INS—prostate cancer	3.26e-06	5.95e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ITPR1—prostate cancer	3.24e-06	5.93e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MYC—prostate cancer	3.23e-06	5.91e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—TGFB1—prostate cancer	3.22e-06	5.89e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CREBBP—prostate cancer	3.19e-06	5.83e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MYC—prostate cancer	3.16e-06	5.78e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—EGFR—prostate cancer	3.16e-06	5.78e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TGFB1—prostate cancer	3.15e-06	5.77e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—EGFR—prostate cancer	3.09e-06	5.65e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—TYMS—prostate cancer	3.06e-06	5.6e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GSTM1—prostate cancer	3.03e-06	5.54e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CD—prostate cancer	3.02e-06	5.53e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—KRAS—prostate cancer	2.98e-06	5.46e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—LPL—prostate cancer	2.97e-06	5.44e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—KRAS—prostate cancer	2.92e-06	5.34e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.87e-06	5.25e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—NOS3—prostate cancer	2.86e-06	5.22e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ERCC2—prostate cancer	2.85e-06	5.21e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	2.74e-06	5.02e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	2.68e-06	4.91e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—MTHFR—prostate cancer	2.68e-06	4.9e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—TP53—prostate cancer	2.65e-06	4.85e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CB—prostate cancer	2.64e-06	4.82e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PPARA—prostate cancer	2.63e-06	4.8e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PTGS2—prostate cancer	2.61e-06	4.78e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TP53—prostate cancer	2.59e-06	4.75e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CAV1—prostate cancer	2.47e-06	4.52e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—IL6—prostate cancer	2.43e-06	4.44e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—IL6—prostate cancer	2.38e-06	4.34e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PTEN—prostate cancer	2.28e-06	4.17e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.25e-06	4.11e-05	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—AKT1—prostate cancer	2.24e-06	4.1e-05	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—AKT1—prostate cancer	2.19e-06	4.01e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—EP300—prostate cancer	2.17e-06	3.97e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—INS—prostate cancer	2.13e-06	3.89e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CREBBP—prostate cancer	2.08e-06	3.81e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.98e-06	3.62e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—NOS3—prostate cancer	1.87e-06	3.41e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.72e-06	3.15e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PTGS2—prostate cancer	1.71e-06	3.12e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.61e-06	2.94e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PTEN—prostate cancer	1.49e-06	2.72e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—EP300—prostate cancer	1.42e-06	2.6e-05	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—AKT1—prostate cancer	1.31e-06	2.4e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.05e-06	1.92e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—AKT1—prostate cancer	8.58e-07	1.57e-05	CbGpPWpGaD
